title: [Hemocoagulase in abdominal operation and its effect on hemoagglutination].
abstract: OBJECTIVE
  To evaluate the hemostatic role of hemocoagulase in abdominal operation and its effects on coagulation.
  
  
  METHODS
  180 patients receiving abdominal operation were studied prospectively by randomized, double-blind controlled and multicenter design. They were divided into Hemocoagulase group (60 patients), lizhixue group (60), and manitol hexanitrate group (60). The groups were, observed in terms of the effects on hemostatic time, hemorrhagic volume, hemorrhagic volume per square unit, and body coagulation (BT, CT, PT, APTT and PLT) parameters.
  
  
  RESULTS
  The groups received different drugs. The average hemostatic time in the hemocoagulase group was 121.6 s, hemorrhagic volume was 9.6 g, and hemorrhagic volume per square unit was 0.2 g. The similar results were observed in the lizhixue group (P > 0.05), but they were significantly different (P < 0.05) from those of the manitol hexanitrate group (159.2 s, 12.49 g, 0.3 g). In the hemocoagulase and lizhixue groups hemorrhagic and hemoagglution time decreased 30 minutes and 1 day after operation. This finding was significantly differenct from that in the manitol hexanitrate group (P < 0.05).
  
  
  CONCLUSIONS
  Hemocoagulase plays a good hemostatic role in the hemorrhagic capillary at abdominal incision.
authors.affiliation: Department of General Surgery, Beijing Hospital, Beijing 100730, China.
authors.forename: Mingwei
authors.initials: M
authors.lastname: Zhu
authors.forename: Jinduo
authors.initials: J
authors.lastname: Cao
authors.forename: Zhengeng
authors.initials: Z
authors.lastname: Jia
authors.forename: Zhiquan
authors.initials: Z
authors.lastname: Duan
authors.forename: Guojin
authors.initials: G
authors.lastname: Liu
authors.forename: Junmin
authors.initials: J
authors.lastname: Wei
authors.forename: Haikong
authors.initials: H
authors.lastname: Long
mesh_terms: D000005:Abdomen; D000293:Adolescent; D000328:Adult; D000368:Aged; D012103:Batroxobin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001777:Blood Coagulation / Q000187:drug effects*; D004311:Double-Blind Method; D005260:Female; D006488:Hemostasis, Surgical / Q000379:methods*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
chemical_list: D006490:Hemostatics; D012103:Batroxobin